Company Overview
- Headquarters
- 795 San Antonio Rd, Palo Alto CA
- Website
- immune-onc.com
- Phone
- (650) 457-1741
- Employees
- 23
- Founded in
- 2016
- Industry
- Materials/Manufacturing
- NAICS Code
-
NAICS Code 541714 CompaniesNAICS Code 5417 CompaniesNAICS Code 54 CompaniesNAICS Code 54171 CompaniesNAICS Code 541 Companies
- SIC Code
-
SIC Code 87 CompaniesSIC Code 873 Companies
Financials & Stats
Revenue
$7B
Total Funding Amount
$138M
Who is ImmuneOnc Therapeutics
Immune-Onc Therapeutics, Inc. is a private clinical-stage oncology company headquartered in Palo Alto, California. Founded in 2017, Immune-Onc employs 23 individuals and generates approximately $7 million in annual revenue. Immune-Onc focuses on discovering and developing novel biotherapeutics targeting myeloid cell inhibitory receptors. Their therapeutic pipeline features several promising candidates, including IO-108, a Phase 1b/2 clinical trial drug targeting LILRB2 for solid tumors, and IO-202, a Phase 1b clinical trial drug targeting LILRB4 for acute myeloid leukemia, chronic myelomonocytic leukemia, and solid tumors. The company's platform approach has led to the development of IO-106, targeting LAIR1, IO-312, a bispecific antibody targeting LILRB4 and CD3, and several undisclosed immunology and oncology programs. For more information, please visit www.immune-onc.com.
Company Leadership
ImmuneOnc Therapeutics Industry Tags
ImmuneOnc Therapeutics Tech Stack
Companies Similar to ImmuneOnc Therapeutics
Analyze industry trends and opportunities by examining competitors and companies comparable to ImmuneOnc Therapeutics, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 7M | 27 | Chino Hills, CA | 1998 | |
| 7M | New York, NY | |||
| 7M | 4 | Cupertino, CA | 2013 | |
| 7M | 3 | 2015 | ||
| 7M | 16 | Providence, RI | 1920 |